Trial Profile
Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs MVI 816 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 30 Jun 2020 Status changed from active, no longer recruiting to completed.
- 12 May 2020 Planned End Date changed from 1 Apr 2020 to 1 May 2020.
- 12 May 2020 Planned primary completion date changed from 1 Apr 2020 to 1 May 2020.